L-Arginine ameliorates oxidative stress in alloxan-induced experimental diabetes mellitus

Journal of Applied Toxicology

Volumn 24, Issue 2, 2004, Pages 93-97

  El Missiry, M A ^a   Othman, A I ^a   Amer, M A ^a  

^a Mansoura University   (Egypt)

Author keywords

Antioxidants; Cholesterol; Free radicals; Glucose; Lipid peroxidation

Indexed keywords

ALLOXAN; ARGININE; CATALASE; CHOLESTEROL; GLUCOSE; GLUTATHIONE; LIPID; NITRIC OXIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; BRAIN; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LIPID PEROXIDATION; LIVER; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; RAT;

ALLOXAN; ANIMALS; ANTIOXIDANTS; ARGININE; BLOOD GLUCOSE; BRAIN; CATALASE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GLUTATHIONE; LIVER; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

FELIS CATUS;

EID: 1842817593     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jat.952     Document Type: Article

References (45)

1. Baynes JW. 1991. Role of oxidative stress in the development of complication in diabetes. Diabetes 40: 405-412.
2. Baynes JW. 1995. Reactive oxygen in the etiology and complications of diabetes: drugs, diet and disease. In Mechanistic Approach to Diabetes, vol. 2, Toannides C, Flatt PR (eds). Ellis Harwood: London; 405-412.
3. Beutler E. 1982. Red Cell Metabolism. A Manual of Biochemical Methods, Beutler E (ed.). Grune and Stratton: New York; 137-140.
4. Blum J, Fridovich I. 1985. Inactivation of glutathione peroxidase by superoxide radical. Arch. Biochem. Biophys. 240: 500-508.
5. Bock PP, Karmer R, Pavelka M. 1980. A simple assay for catalase determination. Cell Biol. Monogr. 7: 44-74.
6. Brandes RP, Brandes S, Boger RH, Bode-Boger SM, Mugge A. 2000. L-Arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix. Life Sci. 66: 1519-1524.
7. Bromme HJ, Morke W, Peschke D, Ebelt H, Peschke D. 2000. Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. Pineal Res. 29: 201-208.
8. Bromme HJ, Weinandy R, Peschke D, Peschke E. 2001. Simultaneous quantitative determination of alloxan, GSH and GSSG by HPLC. Estimation of the frequency of redox cycling between alloxan and dialuric acid. Horm. Metab. Res. 33: 106-109.
9. Cheeseman KH. 1994. Initiation and pathobiological consequence of lipid peroxidation. In Free Radicals in the Environment: Medicine and Toxicology, Nohl H, Esterbauer H, Rice-Evans C (eds). Richelieu Press: London; 81-90.
10. Chiueh CC. 1999. Neuroprotective properties of nitric oxide. Ann. NY Acad. Sci. 890: 301-311.
11. El-Missiry MA. 1999. Enhanced testicular antioxidant system by ascorbic acid in alloxan diabetic rats. Comp. Biochem. Physiol. C 119: 233-237.
12. El-Missiry MA, El-Gendy AM. 2000. Amelioration of alloxan induced diabetes mellitus and oxidative stress in rats by oil of Eruca sativa seeds. Ann. Nutr. Metab. 44: 97-100.
13. Esterbauer H, Zollner H, Schaur RJ. 1990. Lipid Oxidation, Vigo C, Pel Frey BA (eds). CRC Press: Boca Raton, FL.
14. Faldetta M, Laurenti O, Desideri G, Bravi M, De Luca O, Marinucci M, De Mattia G, Ferri C. 2002. L-Arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in type II diabetic patients. Diabetologia 45: 1120-1127.
15. Farbiszewski R, Bielawska A, Szymanska M, Skrzydlewska E. 1996. Spermine partially normalizes in vivo antioxidant defense potential in certain brain regions in transiently hypoperfused rat brain. Neurochem. Res. 21: 1497-1503.
16. Fisher J, Humburger SA. 1980. Inhibition of alloxan action in isolated pancreatic islets by superoxide dismutase, catalase, and metal chelator. Diabetes 29: 213-216.
17. 2+/EDRF signaling are due to generation of superoxide anion. Diabetes 45: 1386-1395.
18. 252 mutation in insulin receptors from a patient with severe insulin resistance inhibits receptor internalisation but preserves signalling events. Diabetologia 45: 657-667.
19. Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ. 1998. Nitric oxide availability in diabetes mellitus. Diab. Metab. Rev. 14: 241-249.
20. Kawano H, Motoyama T, Hirai N, Kugiyama K, Yasue H, Ogawa H. 2002. Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: possible role of oxidative stress. Atherosclerosis 161: 375-380.
21. Kosenko EA, Kaminskii AI, Kaminskii IU. 1999. Activity of antioxidant enzymes in liver and brain is decreased in the early stage of diabetes, and this decrease depends on the function of NMDA-receptors. Vopr. Med. Khim. 45: 304-308.
22. Landmesser U, Merten R, Spiekermann S, Buttner K, Drexler H, Hornig B. 2000. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 101: 2264-2270.
23. Lass A, Suessenbacher A, Wolkart G, Mayer B, Brunner F. 2002. Functional and analytical evidence for scavenging of oxygen radicals by L-arginine. Mol. Pharmacol. 61: 1081-1088.
24. Lovaas E. 1995. Hypothesis: spermine may be an important epidermal antioxidant. Med. Hypoth. 45: 59-67.
25. Lube CB, Hayn M, Kitzmuller E, Vierhapper H, Lubec G. 1997. L-Arginine reduces lipid peroxidation in patient with diabetes mellitus. Free Rad. Biol. Med. 22: 355-357.
26. Mendez JD, Arreola MA. 1992. Effect of L-arginine on pancreatic arginase activity and polyamines in alloxan treated rats. Biochem. Int. 28: 569-575.
27. Mendez JD, Balderas F. 2001. Regulation of hyperglycemia and dyslipidemia by exogenous L-arginine in diabetic rats. Biochimie 83: 453-458.
28. Mendez JD, Palomar-Morales M. 1999. Prevention by L-arginine and polyamines of delayed development and embryotoxicity caused by chemically-induced diabetes in rats. Reprod. Toxicol. 13: 501-509.
29. Mohan IK, Das UN. 1998. Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus. Free Rad. Biol. Med. 25: 757-765.
30. Moncada S, Palmer RM, Higgs EA. 1991. Nitric oxide: Physiology, pathology, and pharmacology. Parmacol. Rev. 43: 109-141.
31. 2+ homeostasis in rat pancreatic beta-cells. Cell Struct. Funct. 25: 187-193.
32. Nishikawa T, Edelstein D, Du XL. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790.
33. Nishikimi M, Rao N, Yagi K. 1972. The occurrence of superoxide anion in the reaction of reduced phenazine methosulphate and molecular oxygen. Biochem. Biophys. Res. Commun. 46: 844-853.
34. Ohkawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxidation in animal tissues by thiobarbituric acid reaction. Ann. Biochem. 95: 351-358.
35. Pieper GM, Pltier BA. 1995. Amelioration by L-arginine of dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J. Cardiovasc. Pharmacol. 25: 397-403.
36. Pieper GM, Siebeneich W, Moore-Hilton G, Roza AM. 1997. Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia 40: 910-915.
37. Popov D, Costache G, Georgescu A, Enache M. 2002. Beneficial effects of L-arginine supplementation in experimental hyperlipemia-hyperglycemia in the hamster. Cell Tissue Res. 308: 109-120.
38. Rodwell VW. 1996. Conversion of amino acid to specialized protein. In Harper's Biochemistry (24th edn), Murray PK, Granner DK, Mayes PA, Rodwell VW (eds). Appleton & Lang: Los Altos, California; 322-343.
39. Santini SA, Marra G, Giardina B, Cotroneo P, Mordente A, Martorana GE, Manto A, Ghirlanda G. 1997. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 46: 1853-1858.
40. Soto CP, Perez B, Favari L, Reyes L. 1998. Prevention of alloxan induced diabetes mellitus in the rats by silymarin. Comp. Biochem. Physiol. C 119: 125-129.
41. Szkudelski T. 2001. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 50: 537-546.
42. Tozer GM, Everett SA. 1997. Nitric oxide in tumour biology and cancer therapy. Part 1: Physiological aspects. Clin. Oncol. 9: 282-293.
43. Trachtman H, Futterweit S, Crimmins DL. 1997. High glucose inhibits nitric oxide production in cultured rat mesangial cells. J. Am. Soc. Nephrol. 8: 1276-1282.
44. Tsai HJ, Shang HF, Yeh CL, Yeh SL. 2002. Effects of arginine supplementation on antioxidant enzyme activity and macrophage response in burned mice. Burns 28: 258-263.
45. Yadav P, Sarkar S, Rathor N, John S, Kale M, Bhatnagar D. 1996. Ascorbic acid counteracts the prooxidant effect of alloxan in erythrocytes in vitro. Curr. Sci. 71: 404-406.